Peer-Reviewed Study in Cell Validates eFFECTOR Therapeutics’ Novel Small-Molecule Approach to Cancer Treatment

SAN DIEGO, June 19, 2015 – eFFECTOR Therapeutics co-founder Davide Ruggero, Ph.D., has published ground-breaking research in the preeminent biomedical journal Cell which demonstrates preclinical promise for a cancer treatment approach that’s centered on selectively regulating the cell’s protein synthesis process, known as translation.

eFFECTOR Therapeutics Raises $45 Million in Series A Financing

San Diego, CA – May 20, 2013 – eFFECTOR Therapeutics, a newly established biopharmaceutical company, today announced the completion of a $45 million Series A financing.  eFFECTOR is focused on inventing and developing small molecule drugs to selectively regulate protein synthesis, also known as translation, with an initial emphasis on cancer.